Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (AU2013271768) Solid forms of an antiviral compound

Office : Australia
Application Number: 2013271768 Application Date: 04.06.2013
Publication Number: 2013271768 Publication Date: 15.01.2015
Publication Kind : B2
Prior PCT appl.: Application Number:US2013044138 ; Publication Number: Click to see the data
IPC:
C07D 471/08
A61K 31/4178
A61P 31/12
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
08
Bridged systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4178
not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
Applicants: Gilead Pharmasset LLC
Inventors:
Agents: FPA Patent Attorneys Pty Ltd
Priority Data: 13/800,374 13.03.2013 US
61/655,934 05.06.2012 US
61/759,295 31.01.2013 US
Title: (EN) Solid forms of an antiviral compound
Abstract: front page image
(EN) Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H- benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: (Compound (I)). Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
Also published as:
CA2875507IL236004EP2855478SG11201408013WCN104379584KR1020150028971
BR112014030400RU2014150437IN2644/MUMNP/2014JP2015518891ES2694759WO/2013/184698